Ocrevus (ocrelizumab) costs

DISEASE INDICATIONS: Multiple Sclerosis MANUFACTURER: Roche Registration Limited USAGE: Intravenous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Therapeutic Goods Administration (TGA) Medsafe (NZ) Ocrevus (ocrelizumab) is a groundbreaking prescription medication used in the treatment of multiple sclerosis (MS). It is a disease-modifying therapy (DMT) designed to alter the course of the disease by suppressing the immune system's abnormal response that leads to damage in the central nervous system. Since its approval, Ocrevus has played a significant role in the management of MS, offering new hope to patients by effectively targeting both relapsing forms and primary progressive forms of the disease.